{"nctId":"NCT01020448","briefTitle":"Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer","startDateStruct":{"date":"2009-11"},"conditions":["Prostate Cancer"],"count":339,"armGroups":[{"label":"Triptorelin (Decapeptyl®) 22.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Triptorelin (Decapeptyl®)"]}],"interventions":[{"name":"Triptorelin (Decapeptyl®)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A histologically confirmed, locally advanced or metastatic prostate cancer, and naïve to androgen deprivation therapy, and a candidate for hormonal treatment.\n* An estimated survival time of at least twelve months according to the investigator's assessment.\n* A performance status score ≤ 2 according to the World Health Organisation (WHO) criteria.\n\nExclusion Criteria:\n\n* Previous surgical castration.\n* Previous or has planned curative prostate cancer therapy (radiation/surgery)\n* Previous hormone therapy (GnRH analogues, estrogens or anti-androgens)\n* Patients with risk of a serious complication in the case of tumour flare (vertebral metastases threatening spinal cord compression or significant obstructive uropathy)","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA","description":"PCA-3 score = (mRNA PCA3/mRNA PSA)x1000\n\n* Non-assessable = Associated PSA mRNA \\<7500 copies/mL\n* ≤BLQ = PCA-3 mRNA is below the concentration of the calibrator and associated PSA mRNA \\>7500 copies/mL\n* \\<35 = PCA-3 mRNA above BLQ and less than 35\n* ≥35 = PCA-3 mRNA greater or equal to 35","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"PCA3 Score Expressed as a Ratio of PCA3 mRNA Over PSA mRNA","description":"PCA-3 score = (mRNA PCA3/mRNA PSA)x1000\n\n* Non-assessable = Associated PSA mRNA \\<7500 copies/mL\n* ≤BLQ = PCA-3 mRNA is below the concentration of the calibrator and associated PSA mRNA \\>7500 copies/mL\n* \\<35 = PCA-3 mRNA above BLQ and less than 35\n* ≥35 = PCA-3 mRNA greater or equal to 35","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"TMPRSS2-ERG Score (Expressed as a Ratio of T2-ERG mRNA Over PSA mRNA)","description":"TMPRSS2-ERG = (TMPRSS2-ERG mRNA / PSA mRNA) x 100000\n\nA TMPRSS2-ERG score \\<35 was described as 'negative' and a TMPRSS2-ERG score ≥35 as 'positive.'","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Medically Castrated (i.e. With Serum Testosterone Levels of <50 ng/dL)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null}]}]}]},{"type":"SECONDARY","title":"PSA Level","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety, Assessed Through the Collection of Adverse Events (AEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"193","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":37,"n":325},"commonTop":["Hot flush"]}}}